NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

IMC-A12 in Treating Patients With Advanced Liver Cancer

Phase 2

Completed

Conditions: Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions: Biological: cixutumumab
Procedure: computed tomography
Procedure: contrast-enhanced magnetic resonance imaging

First Posted Date: 2008-03-20

Last Posted Date: 2014-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00639509

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Exercise and Pioglitazone for HIV-Metabolic Syndromes

Not Applicable

Completed

Conditions: Obesity
Type 2 Diabetes
HIV Infections
HIV
AIDS
Cardiovascular Disease
Lipodystrophy

Interventions: Drug: Pioglitazone
Behavioral: Exercise training

First Posted Date: 2008-03-20

Last Posted Date: 2013-10-23

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 44

Registration Number: NCT00639457

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy

Phase 2

Completed

Conditions: Stage IV Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: saracatinib

First Posted Date: 2008-03-19

Last Posted Date: 2018-08-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00638937

Locations: 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
The Ottawa Hospital Cancer Centre (Ottawa Health Research Institute) Civic Campus, Ottawa, Ontario, Canada
🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

and more 1 locations

A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer

Phase 1

Completed

Conditions: Lobular Breast Carcinoma in Situ
Atypical Ductal Breast Hyperplasia
Breast Cancer
Ductal Breast Carcinoma in Situ

Interventions: Drug: atorvastatin calcium
Other: laboratory biomarker analysis

First Posted Date: 2008-03-18

Last Posted Date: 2016-12-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT00637481

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Satraplatin and Prednisone to Treat Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer
Genetic Polymorphism

Interventions: Drug: Satraplatin
Drug: prednisone

First Posted Date: 2008-03-13

Last Posted Date: 2018-10-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00634647

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Associates in Oncology and Hematology, Rockville, Maryland, United States

Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: mitoxantrone hydrochloride
Drug: carboplatin
Drug: alvocidib
Drug: topotecan hydrochloride
Drug: cytarabine
Drug: sirolimus
Drug: etoposide

First Posted Date: 2008-03-12

Last Posted Date: 2015-07-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 92

Registration Number: NCT00634244

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 17 locations

Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Biological: cetuximab
Drug: bortezomib
Radiation: intensity-modulated radiation therapy
Drug: cisplatin

First Posted Date: 2008-03-05

Last Posted Date: 2011-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00629226

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸
UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Phase 2

Completed

Conditions: Recurrent Thyroid Gland Carcinoma
Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7
Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7
Stage III Thyroid Gland Medullary Carcinoma AJCC v7
Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7
Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7
Stage III Differentiated Thyroid Gland Carcinoma AJCC v7
Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7
Thyroid Gland Anaplastic Carcinoma
Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7

Interventions: Drug: Pazopanib Hydrochloride
Other: Laboratory Biomarker Analysis

First Posted Date: 2008-02-28

Last Posted Date: 2020-02-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 152

Registration Number: NCT00625846

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 19 locations

Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Biological: ziv-aflibercept

First Posted Date: 2008-02-25

Last Posted Date: 2014-02-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT00622414

Locations: 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 3 locations

Cognitive Behavioral Treatment of Depression in ESRD Patients on Dialysis

Not Applicable

Completed

Conditions: End Stage Renal Disease
Depression

Interventions: Behavioral: Cognitive behavioral therapy

First Posted Date: 2008-02-20

Last Posted Date: 2017-09-15

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 65

Registration Number: NCT00618475

Locations: 🇺🇸
Parkside Hemodialysis, Brooklyn, New York, United States

AI-Powered Research

Premium Access

NATIONAL INSTITUTES OF HEALTH

IMC-A12 in Treating Patients With Advanced Liver Cancer

Exercise and Pioglitazone for HIV-Metabolic Syndromes

AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy

A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer

Satraplatin and Prednisone to Treat Prostate Cancer

Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors

Cognitive Behavioral Treatment of Depression in ESRD Patients on Dialysis